2-[[2-[(E)-7-carboxy-5-hydroxyhept-6-enoyl]oxy-3-hexadecanoyloxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 甘油磷脂
• 英文名称: 2-[[2-[(E)-7-carboxy-5-hydroxyhept-6-enoyl]oxy-3-hexadecanoyloxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
• 化学式: C32H61NO11P+
• 分子量: 666.8
• InChiKey: URBBRAZIPCKXJD-GHVJWSGMSA-O

计算性质

• 辛醇/水分配系数(LogP)：
  6
• 重原子数：
  45
• 可旋转键数：
  32
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.84
• 拓扑面积：
  166
• 氢给体数：
  3
• 氢受体数：
  11

文献信息

• STIMULI THAT HYPERACTIVATE RESIDENT DENDRITIC CELLS FOR CANCER IMMUNOTHERAPY
  申请人：CHILDREN'S MEDICAL CENTER CORPORATION

  公开号：EP4061409A1

  公开（公告）日：2022-09-28
• SURFACE-TREATED MAGNESIUM OR CALCIUM ION-CONTAINING MATERIALS AS WHITE PIGMENTS IN ORAL CARE COMPOSITIONS
  申请人：CHILDREN'S MEDICAL CENTER CORPORATION

  公开号：US20220370310A1

  公开（公告）日：2022-11-24

  The present application is related to cancer immunotherapy, e.g. stimulation of T cell mediated anti-tumor therapy. Accordingly, described herein are methods of inducing or enhancing an adaptive immune response to a cancer in a subject and methods of treating cancer in a subject. In some embodiments, the methods hyperactivate dendritic cells (DCs), which induce T helper type I (TH1) and cytotoxic T lymphocyte (CTL) responses in the absence of TH2 immunity.
• Hyperactive Dendritic Cells Enable Durable Adoptive Cell Transfer-Based Anti-Tumor Immunity
  申请人：Children's Medical Center Corporation

  公开号：US20220401535A1

  公开（公告）日：2022-12-22

  The present application is related to cancer immunotherapy, e.g. stimulation of T cell mediated anti-tumor therapy.
• [EN] STIMULI THAT HYPERACTIVATE RESIDENT DENDRITIC CELLS FOR CANCER IMMUNOTHERAPY<br/>[FR] STIMULI HYPERACTIVANT DES CELLULES DENDRITIQUES RÉSIDENTES POUR L'IMMUNOTHÉRAPIE ANTICANCÉREUSE
  申请人：CHILDRENS MEDICAL CENTER

  公开号：WO2021102058A1

  公开（公告）日：2021-05-27

  The present application is related to cancer immunotherapy, e.g. stimulation of T cell mediated anti-tumor therapy. Accordingly, described herein are methods of inducing or enhancing an adaptive immune response to a cancer in a subject and methods of treating cancer in a subject. In some embodiments, the methods hyperactivate dendritic cells (DCs), which induce T helper type I (TH1) and cytotoxic T lymphocyte (CTL) responses in the absence of TH2 immunity.
• [EN] HYPERACTIVE DENDRITIC CELLS ENABLE DURABLE ADOPTIVE CELL TRANSFER-BASED ANTI-TUMOR IMMUNITY<br/>[FR] CELLULES DENDRITIQUES HYPERACTIVES PERMETTANT UNE IMMUNITÉ ANTITUMORALE DURABLE BASÉE SUR LE TRANSFERT ADOPTIF DE CELLULES
  申请人：CHILDRENS MEDICAL CENTER

  公开号：WO2021102057A1

  公开（公告）日：2021-05-27

  The present application is related to cancer immunotherapy, e.g. stimulation of T cell mediated anti-tumor therapy.